Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Data from the pivotal Phase I trial studying crizotinib in NSCLC patients demonstrates significant increase in one- and two-year survival against historical controls.

You may also be interested in...



Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson: (Part 2 Of 2)

R&D head reflects on the accelerated approval program in the wake of FDA's February meeting with ODAC.

Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson: (Part 2 Of 2)

R&D head reflects on the accelerated approval program in the wake of FDA's February meeting with ODAC.

Pfizer’s Crizotinib Eases Past FDA With Targeted Population

FDA is showing for the second time in as many weeks that all things are possible when it comes to clearing targeted oncologics with compelling evidence. The agency cleared Pfizer’s Xalkori (crizotinib) for late-stage non-small cell lung cancer Aug. 26, just under five months from submission and based on early stage evidence.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS072260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel